5369-17-5

Basic information

• Product Name: m-butylaniline
• Synonyms: m-butylaniline;3-Butylaniline;Einecs 226-360-0;3-butylBenzenamine;3-n-Butylaniline
• CAS NO: 5369-17-5
• Molecular Formula: C₁₀H₁₅N
• Molecular Weight: 149.2328
• EINECS: 226-360-0
• Mol File: 5369-17-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 252.6°Cat760mmHg
• Flash Point: 107°C
• Appearance: /
• Density: 0.947g/cm³
• Vapor Pressure: 0.0192mmHg at 25°C
• Refractive Index: 1.538
• CAS DataBase Reference: m-butylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: m-butylaniline(5369-17-5)
• EPA Substance Registry System: m-butylaniline(5369-17-5)

Safety Data

• Hazardous Substances Data: 5369-17-5(Hazardous Substances Data)

Usage

General Description

M-butylaniline is a chemical compound with the molecular formula C10H15N. It is an aromatic amine that is used in the production of dyes, pharmaceuticals, and other organic compounds. m-butylaniline has a clear to yellowish liquid appearance with a sweet, aromatic odor. M-butylaniline is primarily utilized as an intermediate in the manufacturing of dyes, and it also serves as a building block for the synthesis of various drugs and agrochemicals. It is important to handle m-butylaniline with care as it can be harmful if ingested, inhaled, or exposed to the skin and eyes. Proper safety measures should be taken when working with this chemical to minimize potential health risks.

InChI:InChI=1/C10H15N/c1-2-3-5-9-6-4-7-10(11)8-9/h4,6-8H,2-3,5,11H2,1H3

Upstream product

• 50766-86-4 1-(3-nitrophenyl)-1-butanone 
• 20651-76-7 1-butyl-3-nitro-benzene 
• 2034-41-5 1-(3-aminophenyl)butan-1-one 
• 698378-33-5 (2R)-2-{[(1R)-1-(3-nitrophenyl)-3-butenyl]amino}-2-phenylethanamide 
• 99-61-6 3-nitro-benzaldehyde 
• 698377-63-8 (2R)-2-{[(E)-(3-nitrophenyl)methylidene]amino}-2-phenylacetamide 
• 104-13-2 4-Butylaniline 
• 20651-75-6 1-butyl-4-nitro-benzene 
• 104-51-8 1-butylbenzene 
• 642471-14-5 3-(2-butenyl)nitrobenzene 
• 103264-00-2 1-(buta-1,3-dien-1-yl)-3-nitrobenzene 
• 119273-80-2 β-ethyl-3-nitrostyrene 
• 62-53-3 aniline 
• 1126-78-9 N-(n-butyl)aniline 

Downstream Products

• 1035452-31-3 C₁₀H₁₆N₂*ClH 
• 17332-53-5 2-((3-butylphenyl)amino)benzoic acid 
• 20651-66-5 3-(n-butyl)fluorobenzene 
• 87986-22-9 6-(3-Butyl-phenylamino)-1H-pyrimidine-2,4-dione 
• 7661-52-1 7-butylquinoline 

Relevant articles and documents

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

The YAP-TEAD transcriptional complex is responsible for the expression of genes that regulate cancer cell growth and proliferation. Dysregulation of the Hippo pathway due to overexpression of TEAD has been reported in a wide range of cancers. Inhibition of TEAD represses the expression of associated genes, demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization experiments confirmed that LM98 is anchored within the palmitic acid pocket of TEAD. LM98 reduces the expression of CTGF and Cyr61, inhibits MDA-MB-231 breast cancer cell migration and arrests cell cycling in the S phase during cell division.

PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS

The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders

4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C 1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II STR1 wherein R 2 represents carboxy or a group convertible thereto in vivo, R 6 is hydrogen and R 5 and R 7 represent C 1-6 alkyl or halogen, provided that R 5 and R 7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.